Apotex Sets Stage For Next Fed. Circ. BPCIA Dispute
Last October, Apotex Inc. filed an abbreviated biologic license application (aBLA) seeking to market a biosimilar version of Amgen Inc.'s Neulasta. Apotex's application was accepted for review in December 2014, and Apotex...To view the full article, register now.
Already a subscriber? Click here to view full article